Latest Headlines

Latest Headlines

Celgene fights for sanction on patent challenger Bass

Celgene is hedge fund manager Kyle Bass' latest patent target, it says--but the biotech isn't taking the news lying down.

Celgene's $7.2B buyout gets a big thumbs up, but is the deal really done?

Generally, multibillion-dollar biotech deals these days come with a considerable amount of light scolding from analysts fretting over the cost as valuations surge. Downside remarks tend to caution against looking for a higher share price, and one analyst at least raises the prospect that the bidding war may not be over. Here's a selection of notable comments this morning.

Celgene chief Bob Hugin isn't done betting on 'binary' biotech deals

By all accounts, the bidding war for Receptos was intense. But for Celgene CEO Bob Hugin and his go-to deals chief George Golumbeski, strategically this was exactly the right time to clinch a $7.2 billion buyout deal for the biotech and its lead drug ozanimod. And after they add this latest late-stage program to the pipeline, there are still more deals to be done.

UPDATED: Celgene shells out $7.2B for Receptos in a big bet on autoimmune disease

Celgene is trading $7.2 billion in cash for Receptos and its Phase III autoimmune treatment, building on some recent success in the field.

Biopharma's 10 highest-paid heads of R&D

The year's 10 highest-paid development executives pulled in $124.4 million in total compensation, a roughly 35% jump over 2013's top earners. And while each entrant benefited from meeting individual company goals, the whole group benefited from biopharma's macroeconomic moment in the sun, as the value of stock awards skyrocketed alongside the industry index.

Celgene recommits to Epizyme, adding $620M in cancer drug bonuses

Three years after stepping up with a $250 million deal--with $90 million upfront--Celgene has remapped its partnership with Epizyme, extending their collaboration three more years. Under this new deal, Cambridge, MA-based Epizyme gets $10 million cash with up to $610 million in milestones for three histone methyltransferase inhibitor targets.

Celgene throws down millions to snag prime airtime for its psoriasis-fighter

As the market for psoriasis meds heats up, companies are throwing down some hefty chunks of change to snag airtime for their TV spots.

Hot summer ad wars: Celgene launches Otezla DTC into crowded psoriasis drug market

Celgene's Otezla is the newest entrant in what is shaping up to be a summer throwdown among psoriasis drugmakers. Not surprisingly, every company's got its own strategy.

Fast-growing Celgene snaps up Merck's abandoned NJ campus

Out with the old guard, in with the new. In another sign that Big Biotech is elbowing into the top levels of pharma, Celgene has agreed to buy Merck & Co.'s old campus in Summit, NJ, adding the sprawling 1.3-million-square-foot complex to its already growing operations in the city.

A booming Celgene grabs Merck's abandoned campus in New Jersey

Fresh off a landmark $1 billion deal to buy into Juno's immuno-oncology pipeline, fast-growing Celgene has inked another contract to buy up Merck's sprawling old campus in Summit, NJ.